Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
Clinical Gastroenterology and Hepatology · 2023-05 · 21 (5) · 1330-1337.e2
DOI: 10.1016/j.cgh.2022.09.008 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-05. Verfasst von Byron P Vaughn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota. Electronic address: bvaughn@umn.edu. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) emerged as rescue treatment for multiply recurrent Clostridioides difficile infections (rCDIs) nonresponsive to standard therapy. However, estimation of FMT efficacy varies among different protocols and formulations, while placebo-controlled clinical trials have excluded most rCDI patients because of medical comorbidities. This study aimed to determine the safety and effectiveness of capsule FMT (cap-FMT) and colonoscopy FMT (colo-FMT) for rCDI using standardized products in a large, multicenter, prospective, real-world cohort. METHODS: Clinical outcomes and adverse events after FMT performed for rCDI at 6 sites were captured in a prospective registry. FMT was performed using 1 of 2 standardized formulations of microbiota manufactured by the University of Minnesota Microbiota Therapeutics Program, freeze-dried/encapsulated or frozen-thawed/liquid. The FMT administration route was determined by the treating physician. The rCDI cure rate was assessed at 1 and 2 months. Safety data were collected within the first 72 hours and at 1 and 2 months. Logistic regression was used to investigate factors associated with FMT failure. RESULTS: A total of 301 FMTs were performed in 269 unique patients. Two-thirds were cap-FMT. CDI cure rates were 86% (95% CI, 82%-90%) at 1 month and 81% (95% CI, 75%-86%) at 2 months. There was no difference in the 1-month or 2-month cure rate between cap-FMT and colo-FMT. Cap-FMT recipients were older and less likely to be immunosuppressed or have inflammatory bowel disease. Patient factors of older age and hemodialysis were associated with FMT failure by 2 months on multivariate logistic regression. In addition, post-FMT antibiotic use was associated with FMT failure at 2 months. One serious adverse event was related to colonoscopy (aspiration pneumonia), otherwise no new safety signals were identified. CONCLUSIONS: Cap-FMT using freeze-dried capsules has a similar safety and effectiveness profile compared with colo-FMT, without the procedural risks of colonoscopy. Although highly effective overall, patient selection is a key factor to optimizing FMT success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota. Electronic address: bvaughn@umn.edu.
- Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana.
- Division of Gastroenterology, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota.
- Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota; Center for Immunology, University of Minnesota, Minneapolis, Minnesota; BioTechnology Institute, University of Mi…
Zitieren
APA
Vaughn, B. P., Fischer, M., Kelly, C. R., Allegretti, J. R., Graiziger, C., Thomas, J., McClure, E., Kabage, A. J., & Khoruts, A. (2023). Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Clinical Gastroenterology and Hepatology, 21(5), 1330-1337.e2. https://doi.org/10.1016/j.cgh.2022.09.008
Vancouver
Vaughn BP, Fischer M, Kelly CR, Allegretti JR, Graiziger C, Thomas J, et al. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Clinical Gastroenterology and Hepatology. 2023;21(5):1330-1337.e2. doi:10.1016/j.cgh.2022.09.008
BibTeX
@article{Vaughn2023,
author = {Vaughn, Byron P and Fischer, Monika and Kelly, Colleen R and Allegretti, Jessica R and Graiziger, Carolyn and Thomas, Juana and McClure, Emma and Kabage, Amanda J and Khoruts, Alexander},
title = {Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
volume = {21},
number = {5},
pages = {1330--1337.e2},
doi = {10.1016/j.cgh.2022.09.008}
}
EUVIMED